ConductScience.org, home

Paper38548752

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.

Hayes TK and 26 others. Nat Commun, 2024. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. Papers, record 38548752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38548752

Download JSON
Disease
glioblastoma453 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
PubMed
Journal
Nat Commun
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
3.88, provisional
iCite
Revised in PubMed
2025-07-21
PubMed

Authors27

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hayes TKTikvah K
2Aquilanti EElisa
3Persky NSNicole S
4Yang XXiaopinghttps://orcid.org/0000-0002-6811-4915
5Kim EEErica E
6Brenan LLisa
7Goodale ABAmy B
8Alan DDouglas
9Sharpe TTed
10Shue RERobert E
11Westlake LLindsay
12Golomb LLior
13Silverman BRBrianna R
14Morris MDMyshal D
15Fisher TRTy Running
16Beyene EEden
17Li YYYvonne Yhttps://orcid.org/0000-0002-1741-1995
18Cherniack ADAndrew Dhttps://orcid.org/0000-0003-0470-0111
19Piccioni FFedericahttps://orcid.org/0000-0003-1210-3210
20Hicks JKJ Kevin

Source PubMed

See all 27 authorsDownload CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GlioblastomaMajor topic
Lung NeoplasmsMajor topic
Humans
Protein Kinase Inhibitors
ErbB Receptors
Mutation

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K99 CA248836NCI NIH HHSUnited StatesK99CA248836PubMed and NIHNIH RePORTER
R00 CA248836NCI NIH HHSUnited StatesK99CA248836PubMed and NIHNIH RePORTER
R35 CA197568NCI NIH HHSUnited StatesR35CA197568PubMed and NIHNIH RePORTER
T32 CA009172NCI NIH HHSUnited StatesT32CA009172PubMedNIH RePORTER
R00CA248836NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01112527PF-00299804 in Adult Patients With Relapsed/Recurrent GlioblastomaDerived from the trial

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in38627431Author Correction: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.https://conductscience.org/library/papers/38627431

Source PubMed

Download CSV of comments and corrections

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124120142The somatic genomic landscape of glioblastoma.Cell2013https://conductscience.org/library/papers/24120142PubMed
217177598Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.PLoS Med2006https://conductscience.org/library/papers/17177598PubMed
315118073Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med2004https://conductscience.org/library/papers/15118073PubMed
426286086EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.Cancer Discov2015https://conductscience.org/library/papers/26286086PubMed
527102076EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.Cancer Discov2016https://conductscience.org/library/papers/27102076PubMed
618403609EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.J Mol Diagn2008https://conductscience.org/library/papers/18403609PubMed
716730237The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.Cancer Cell2006https://conductscience.org/library/papers/16730237PubMed
822588883Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.Cancer Discov2012https://conductscience.org/library/papers/22588883PubMed
928481359Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Nat Med2017https://conductscience.org/library/papers/28481359PubMed
1028979142The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive.Onco Targets Ther2017https://conductscience.org/library/papers/28979142PubMed
1132014348Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.Clin Lung Cancer2020https://conductscience.org/library/papers/32014348PubMed
1231092401Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.Cancer Discov2019https://conductscience.org/library/papers/31092401PubMed
1319692680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
1431751012Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.N Engl J Med2020https://conductscience.org/library/papers/31751012PubMed
1522285168
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol2012https://conductscience.org/library/papers/22285168PubMed
1626051236Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.Lancet Oncol2015https://conductscience.org/library/papers/26051236PubMed
1732923886Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma.JCO Precis Oncol2020https://conductscience.org/library/papers/32923886PubMed
1834526717Structure-based classification predicts drug response in EGFR-mutant NSCLC.Nature2021https://conductscience.org/library/papers/34526717PubMed
1929141884A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.Sci Transl Med2017https://conductscience.org/library/papers/29141884PubMed
2030952700An unbiased in vitro screen for activating epidermal growth factor receptor mutations.J Biol Chem2019https://conductscience.org/library/papers/30952700PubMed

See all 49 referencesDownload CSV of references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
42940191Personalized Therapeutic Strategies in Glioblastoma: Bridging Molecular Markers and In Vivo Observations for Targeted Treatment.Biomedicines2026https://conductscience.org/library/papers/42940191PubMed
42630841Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy.J Natl Cancer Cent2026https://conductscience.org/library/papers/42630841PubMed
42453407Unveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning.Acta Pharm Sin B2026https://conductscience.org/library/papers/42453407PubMed
42249090Integrative structural and dynamics studies of epidermal growth factor receptor (EGFR).Exp Mol Med2026https://conductscience.org/library/papers/42249090PubMed
41951591SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity.Nat Commun2026https://conductscience.org/library/papers/41951591PubMed
41760505Leveraging conformational ensembles in allosteric drug discovery.Trends Pharmacol Sci2026https://conductscience.org/library/papers/41760505PubMed
41644930Advancements in somatic mutation detection through loop-mediated isothermal amplification (LAMP) in human tumors.J Appl Genet2026https://conductscience.org/library/papers/41644930PubMed
41567248Database of recurrent mutations, an unbiased web resource to browse recurrent mutations in cancers.iScience2026https://conductscience.org/library/papers/41567248PubMed
41565660An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression.Nat Commun2026https://conductscience.org/library/papers/41565660PubMed
41278632Uncovering the molecular basis of kinase activity and substrate recognition with phospho-PCA.bioRxiv2025https://conductscience.org/library/papers/41278632PubMed
40872202Bioactive Potential of Nepenthes miranda Flower Extracts: Antidiabetic, Anti-Skin Aging, Cytotoxic, and Dihydroorotase-Inhibitory Activities.Plants (Basel)2025https://conductscience.org/library/papers/40872202PubMed
40866630ECM-based molecular subtypes define prognostic, EMT status, and therapeutic diversity in IDH-mutant gliomas.NPJ Precis Oncol2025https://conductscience.org/library/papers/40866630PubMed
40744495A side-by-side comparison of variant function measurements using deep mutational scanning and base editing.Nucleic Acids Res2025https://conductscience.org/library/papers/40744495PubMed
40724977CNS Tumor with BCOR/BCORL1 Fusion: A Rare Tumor Entity.Int J Mol Sci2025https://conductscience.org/library/papers/40724977PubMed
40617976Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing.Int J Clin Oncol2025https://conductscience.org/library/papers/40617976PubMed
40430991Inhibition of RPA32 and Cytotoxic Effects of the Carnivorous Plant Sarracenia purpurea Root Extract in Non-Small-Cell Lung Cancer Cells.Plants (Basel)2025https://conductscience.org/library/papers/40430991PubMed
40182139Pancreatic Cancer: Pathogenesis and Clinical Studies.MedComm (2020)2025https://conductscience.org/library/papers/40182139PubMed
40053698Prospective Evaluation of Structure-Based Simulations Reveal Their Ability to Predict the Impact of Kinase Mutations on Inhibitor Binding.J Phys Chem B2025https://conductscience.org/library/papers/40053698PubMed
39727987Towards Effective Treatment of Glioblastoma: The Role of Combination Therapies and the Potential of Phytotherapy and Micotherapy.Curr Issues Mol Biol2024https://conductscience.org/library/papers/39727987PubMed
39695128USP21-EGFR signaling axis is functionally implicated in metastatic colorectal cancer.Cell Death Discov2024https://conductscience.org/library/papers/39695128PubMed

See all 24 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
DACOMITINIB ANHYDROUSCHEMBL2110732Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2110732

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38548752

GET https://conductscience.org/api/papers/v1/38548752/authors?page=2